Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz, Gürsoy; Bayer, Atilla; Boran, Çetin; Serin, Didem; Kükner, Aysel; Elçioğlu, Mustafa Nuri

doi:10.1159/000126078

Cited by 8 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The type and incidence of the treatment-related adverse events were in agreement with previous studies [34-37], with conjunctival hyperemia the most commonly reported ocular adverse event. It should be pointed out that, despite the relatively high overall incidence, the majority of reported hyperemia cases were trace or mild, and most of the patients with a hyperemia increase from baseline had only a 0.5-grade increment.…”

Section: Discussionsupporting

confidence: 90%

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Wang

Yuan

et al. 2014

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.MethodsTwo hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.ResultsAmong 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.ConclusionsOur results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Wang

Yuan

et al. 2014

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The present study aimed to explore another type of stimulation on this CALT structure, namely of toxic origin such as that induced by the well-recognized contact irritant BAK, and to compare it with the effects of various BAK-containing antiglaucomatous eyedrops. We mainly focused on the main prostaglandin analogs (PGA) currently available worldwide, as belonging to the major family of antiglaucomatous drugs and as they present different biochemical properties and irritant features [15], [16]. Interestingly, these eyedrops differ from one another in their BAK concentration and may provide interesting comparative information on CALT involvement.…”

Section: Introductionmentioning

confidence: 99%

Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study

et al. 2012

View full text Add to dashboard Cite

Conjunctiva-associated lymphoid tissue (CALT) is closely associated with ocular surface immunity. This study investigated the effects of antiglaucoma prostaglandin analogs with or without benzalkonium chloride (BAK) preservative on organized CALT using an acute toxic model. A total of 48 albino rabbits were used and seven groups of treatments were constituted. Solutions (50 µl) of PBS, 0.02%BAK, 0.02%BAK+latanoprost, 0.015%BAK+travoprost, 0.005%BAK+bimatoprost, BAK-freetravoprost preserved with the SofZia® system or BAK-freetafluprost were instilled 15 times at 5-min intervals in both eyes. CALT changes were analyzed using in vivo confocal microscopy (IVCM), immunohistology in cryosections for detecting MUC-5AC+ mucocytes and CD45+ hematopoietic cells. Antiglaucoma eye drops stimulated inflammatory cell infiltration in the CALT, and seemed to be primarily related to the concentration of their BAK content. The CALT reaction after instillation of BAK-containing eye drops was characterized by inflammatory cell infiltration in the dome and intrafollicular layers and by cell circulation inside the lymph vessels. CD45 was strongly expressed in the CALT after instillation of all BAK-containing solutions at 4 h and decreased at 24 h. The number of MUC-5AC+ mucocytes around the CALT structure decreased dramatically after instillation of BAK-containing solutions. This study showed for the first time the in vivo aspect of rabbit CALT after toxic stimuli, confirming the concentration-dependent toxic effects of BAK. IVCM-CALT analysis could be a pertinent tool in the future for understanding the immunotoxicologic challenges in the ocular surface and would provide useful criteria for evaluating newly developed eye drops.

show abstract

“…The mean reduction in Schirmer's was greater in the timolol group at both 3 months and 6 months and it was statistically significant. 17 The rose bengal scores continued to rise over the period of 6 months in the timolol group. In the bimatoprost group, increase in scores were seen later towards the 6 months.…”

Section: Discussionmentioning

confidence: 89%

A Study of the Effects of Topical Timolol 0.5% and Bimatoprost 0.03% on the Ocular Surface

Mathew¹,

Kumar²,

Batra³

et al. 2017

jebmh

View full text Add to dashboard Cite

BACKGROUNDAntiglaucoma medications have increased in number and use over the past two decades. Timolol and bimatoprost are used as first line therapy in many centres. Adverse effects on the ocular surface have been noted with many topical medications.The aim of the study is to study the effects of timolol and bimatoprost on the ocular surface. MATERIALS AND METHODSNewly-diagnosed patients with POAG were randomly allocated to receive timolol or bimatoprost. Conjunctival impression cytology, tear film break-up time, Schirmer's and rose bengal score were done at baseline, one, three and six months. RESULTSThe tear film break-up time reduced in both groups over the study period with the reduction in the timolol group of 7.3 seconds being more pronounced and statistically significant. The mean reduction in Schirmer test values was greater in the timolol group (9.1 mm) at both 3 months and 6 months and was statistically significant. The rose bengal scores over the period of six months in both groups were being statistically significant at three and six months in the timolol group, while rise in scores was seen only at six months in the bimatoprost group. Conjunctival impression cytology was carried out at baseline and six months. Statistically, significant cytological changes were seen only in the timolol group after six months of therapy. CONCLUSIONThe adverse effects on ocular surface were more pronounced with timolol when compared with bimatoprost.

show abstract

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Cited by 8 publications

References 64 publications

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study

A Study of the Effects of Topical Timolol 0.5% and Bimatoprost 0.03% on the Ocular Surface

Contact Info

Product

Resources

About